Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¸®³×Á¹¸®µå º¹¿ë ÈÄ ¹ß»ýÇÑ ½Ã½Å°æº´Áõ Optic Neuropathy after Taking Linezolid

´ëÇѾȰúÇÐȸÁö 2019³â 60±Ç 12È£ p.1363 ~ 1368
À±¿ä¼Á, ÀÌâ±Ô,
¼Ò¼Ó »ó¼¼Á¤º¸
À±¿ä¼Á ( Yoon Yo-Sep ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¿ï»ê´ëÇб³º´¿ø ¾È°úÇб³½Ç

ÀÌâ±Ô ( Lee Chang-Kyu ) 
¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¿ï»ê´ëÇб³º´¿ø ¾È°úÇб³½Ç

Abstract

¸ñÀû: ±¤¹üÀ§¾àÁ¦³»¼ºÀü °áÇÙ Ä¡·á·Î ¸®³×Á¹¸®µå¸¦ º¹¿ëÇÑ È¯ÀÚ¿¡¼­ ¹ß»ýÇÑ ½Ã½Å°æº´Áõ 1¿¹¸¦ º¸°íÇÏ°íÀÚ ÇÑ´Ù.

Áõ·Ê¿ä¾à: ´Ù¸¥ ±âÀúÁúȯÀÌ ¾ø´ø 61¼¼ ³²ÀÚ È¯ÀÚ·Î 1ÁÖÀÏ ÀüºÎÅÍ ¼­¼­È÷ °¨¼ÒÇÑ ½Ã·ÂÀ» ÁÖ¼Ò·Î ³»¿øÇÏ¿´´Ù. 6°³¿ù Àü ±¤¹üÀ§¾àÁ¦³»¼º Àü °áÇÙÀ¸·Î Áø´Ü¹Þ¾Æ Ÿ º´¿ø¿¡¼­ °áÇÙ¾àÀ» º¹¿ëÇÏ¿´´Ù. µ¶¼º½Ã½Å°æº´ÁõÀ» À¯¹ßÇÏ´Â ´ëÇ¥ÀûÀÎ ¾àÁ¦ÀÎ ¿¡Å½ºÎÅçÀº óÀ½ºÎÅÍ ³»¼ºÀÌ ÀÖ¾î º¹¿ëÇÏÁö ¾Ê¾Ò°í, ¸®³×Á¹¸®µå¸¦ Æ÷ÇÔÇÑ °áÇÙ ¾à¹°À» Áö¼ÓÀûÀ¸·Î º¹¿ëÇÏ¿´´Ù. ³»¿ø ´ç½Ã ȯÀÚÀÇ ÃÖ´ë±³Á¤½Ã·ÂÀº ¾ç¾È 20/400À¸·Î ÃøÁ¤µÇ¾ú´Ù. À̽ÃÇ϶ó»ö°¢°Ë»ç¿¡¼­ ¾ç¾È ½ÉÇÑ »ö°¢ ÀÌ»ó ¼Ò°ßÀ» º¸¿´´Ù. »ó´ë ±¸½Éµ¿°ø¿îµ¿Àå¾Ö´Â ¾ø¾ú°í ¾ÈÀú°Ë»ç»ó ¾ç¾È ½Ã½Å°æÀ¯µÎ¿¡ °æµµÀÇ ÃæÇ÷ ¼Ò°ßÀ» º¸¿´°í, ½Ã¾ß°Ë»ç»ó ¾çÃø ¸ðµÎ Á᫐ ½Ã¾ß °á¼Õ ¼Ò°ßÀ» º¸¿´´Ù. ¸®³×Á¹¸®µå¿¡ ÀÇÇÑ ½Ã½Å°æº´ÁõÀ¸·Î ÀÇ½ÉµÇ¾î ¾à¹°À» Áï½Ã Áß´ÜÇÏ¿´°í, ÇÑ ´Þ ÀÌÈÄ È¯ÀÚÀÇ ÃÖ´ë±³Á¤½Ã·ÂÀº ¾ç¾È 20/20À¸·Î ȸº¹µÇ¾ú°í, 3°³¿ù°´Â ½Ã¾ß ¹× »ö°¢µµ Á¤»óÀ¸·Î ȸº¹µÇ¾ú´Ù.

°á·Ð: ¸®³×Á¹¸®µå´Â ³ÐÀº ½ºÆåÆ®·³À» °¡Áö´Â Ç×»ýÁ¦·Î½á ±¤¹üÀ§³»¼º°áÇÙ Ä¡·á¿¡µµ À¯¿ëÇÏ°Ô »ç¿ëµÇ´Â ¾àÀÌ´Ù. ÇÏÁö¸¸ Àå±â°£ »ç¿ë ½Ã ½Ã½Å°æº´ÁõÀ» À¯¹ßÇÒ °¡´É¼ºÀÌ ÀÖÀ¸¹Ç·Î ±¹³»¿¡¼­ À¯º´·üÀÌ ³ôÀº ³»¼º °áÇÙȯÀڵ鿡¼­ ¸®³×Á¹¸®µå¸¦ Àå±â°£ »ç¿ë ½Ã Ç×»ó ½Ã½Å°æº´ÁõÀÇ °¡´É¼ºÀ» ¿°µÎÇÏ¿©¾ß ÇÑ´Ù. ½Ã½Å°æº´ÁõÀÌ ÀÇ½ÉµÇ¸é ½Å¼ÓÇÑ ¾àÁ¦ÀÇ Áß´ÜÀÌ ÇÊ¿äÇÏ¸ç °¡¿ªÀûÀÎ ÀÓ»ó º¯È­¸¦ ±â´ëÇØ º¼ ¼ö ÀÖ´Ù.

Purpose: We report a case of optic neuropathy in a patient who was treated with pre-extensively drug-resistant tuberculosis (pre-XDR TB) treatment with linezolid.

Case summary: A 61-year-old male patient with no other underlying disease was diagnosed with pre-XDR Tb 6 months before and took the TB drug at another hospital. Ethambolol was not prescribed because it was resistant from the beginning of TB treatment. Threrefore, linezolid was included for treatment of pre-XDR TB. The patient¡¯s best corrected visual acuity was 20/400 in both eyes at the time of outpatient visit. In Ishihara color vision test, both eyes showed complete color blindness. There was no detectable relative afferent pupillary defect, and fundus examination showed hyperemic optic discs and visual field examination showed both central visual field defects. Linezolid induced optic neuropathy was suspected, the drug was discontinued. After one month, the patient's best corrected visual acuity recovered to 20/20 in both eyes, and visual field and color vision returned to normal at 3 months.

Conclusions: Linezolid is a broad spectrum antibiotic and is a useful drug for the treatment of broad-spectrum tuberculosis. However, since long-term use may cause optic neuropathy, the possibility of optic neuropathy should always be considered. If optic neuropathy is suspected, prompt drug withdrawal is required and reversible clinical changes can be expected.

Å°¿öµå

Linezolid induced optic neuropathy; Tuberculo

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS